1st Circ. Affirms Dismissal Of Sarepta Securities Suit
The First Circuit on Tuesday upheld the dismissal of a putative securities class action against drugmaker Sarepta Therapeutics Inc., saying that despite five tries, the plaintiffs failed to plead a "cogent...To view the full article, register now.
Already a subscriber? Click here to view full article